MA53481A - Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde - Google Patents

Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde

Info

Publication number
MA53481A
MA53481A MA053481A MA53481A MA53481A MA 53481 A MA53481 A MA 53481A MA 053481 A MA053481 A MA 053481A MA 53481 A MA53481 A MA 53481A MA 53481 A MA53481 A MA 53481A
Authority
MA
Morocco
Prior art keywords
compositions
methods
rheumatoid arthritis
treating subjects
subjects
Prior art date
Application number
MA053481A
Other languages
English (en)
French (fr)
Inventor
Anita Boyapati
Neil Graham
Toshio Kimura
Jérôme Msihid
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Sanofi Biotechnology filed Critical Regeneron Pharma
Publication of MA53481A publication Critical patent/MA53481A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pathology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
MA053481A 2018-08-29 2019-08-28 Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde MA53481A (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862724212P 2018-08-29 2018-08-29
US201862747301P 2018-10-18 2018-10-18
US201962798697P 2019-01-30 2019-01-30
US201962824399P 2019-03-27 2019-03-27
US201962856431P 2019-06-03 2019-06-03
US201962858443P 2019-06-07 2019-06-07
EP19192387 2019-08-19

Publications (1)

Publication Number Publication Date
MA53481A true MA53481A (fr) 2021-07-07

Family

ID=67851236

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053481A MA53481A (fr) 2018-08-29 2019-08-28 Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde

Country Status (16)

Country Link
US (2) US11319375B2 (https=)
EP (1) EP3843852A1 (https=)
JP (1) JP7504871B2 (https=)
KR (1) KR20210049871A (https=)
CN (1) CN112955222A (https=)
AU (2) AU2019329958B2 (https=)
BR (1) BR112021003206A2 (https=)
CA (1) CA3110891A1 (https=)
CL (1) CL2021000483A1 (https=)
IL (1) IL280824A (https=)
MA (1) MA53481A (https=)
MX (2) MX2021002422A (https=)
PH (1) PH12021550416A1 (https=)
SG (1) SG11202101674QA (https=)
TW (2) TWI868074B (https=)
WO (1) WO2020047029A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020261431A1 (en) 2019-04-24 2021-12-09 Regeneron Pharmaceuticals, Inc. Methods of diagnosis and treatment of rheumatoid arthritis
FR3095698B1 (fr) * 2019-05-03 2021-05-07 Sinnovial Procédé d’estimation de l’efficacité de traitement par un agent anti-CD20 chez un patient atteint de polyarthrite rhumatoïde et en réponse inadéquate a au moins une biothérapie
EP3980459A1 (en) 2019-06-04 2022-04-13 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis
IL298088A (en) * 2020-05-26 2023-01-01 Sanofi Biotechnology The compositions containing an antibody against the interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using them
KR20230031015A (ko) * 2021-08-26 2023-03-07 주식회사 이뮨메드 자가면역질환의 예방 또는 치료를 위한 항체의약품
CN117138126B (zh) * 2023-08-30 2024-04-09 江苏恰瑞生物科技有限公司 定向清除炎症因子il-6的过滤材料及过滤柱

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
EP1097945B1 (en) 1991-03-18 2007-07-04 New York University Monoclonal and chimeric antibody specific for human tumor necrosis factor
EP0628639B1 (en) 1991-04-25 1999-06-23 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
KR100232688B1 (ko) 1992-09-15 1999-12-01 스코트 쥐. 홀퀴스트 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물
PT783893E (pt) 1994-10-07 2012-05-24 Chugai Pharmaceutical Co Ltd Inibição do crescimento anormal das células sinoviais usando antagonistas de il-6 como componente ativo
ZA971600B (en) 1996-02-26 1997-09-22 Merck & Co Inc Treatment of macular edema.
US6670373B1 (en) 1999-10-07 2003-12-30 Eli Lilly And Company Compounds and method for inhibiting MRP1
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
EP2062916A3 (en) 2003-04-09 2009-08-19 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
CN1989439B (zh) 2004-05-06 2010-12-29 美国政府健康及人类服务部 治疗葡萄膜炎的方法以及组合物
EA014226B1 (ru) 2004-07-26 2010-10-29 Байоджен Айдек Ма Инк. Антитела к cd154, их фрагменты и способы применения антител и фрагментов
CN101326195B9 (zh) 2005-12-13 2022-11-11 伊莱利利公司 抗il-17抗体
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
FR2920033B1 (fr) 2007-08-13 2014-08-22 Snecma Turbomachine avec diffuseur
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP4885308B2 (ja) 2009-03-19 2012-02-29 中外製薬株式会社 改良された抗体分子を含有する製剤
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
EP2464666B1 (en) * 2009-07-15 2018-03-21 Eva Kovacs-Benke Combination of a human interleukin-6 antagonist and a human interleukin-6 receptor antagonist in therapy of tumour diseases
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
KR20130065662A (ko) 2010-05-07 2013-06-19 조마 테크놀로지 리미티드 ⅠＬ-1β 관련 병태의 치료 방법
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
EP2670438A4 (en) 2011-02-03 2015-05-20 Santarus Inc SELECTION AND TREATMENT OF PATIENTS
TWI568888B (zh) 2011-09-15 2017-02-01 第諾拉工業公司 氣體擴散電極及其製法和電化電解池
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
CA2922732A1 (en) * 2013-09-03 2015-03-12 L. Douglas GRAHAM Treatment methods for rheumatoid arthritis
AU2014352801B2 (en) * 2013-11-22 2020-05-28 Regeneron Pharmaceuticals, Inc. Compositions for the treatment of rheumatoid arthritis and methods of using same
WO2015116852A1 (en) * 2014-01-29 2015-08-06 Regeneron Pharmaceuticals, Inc. Methods for treating rheumatoid arthritis by administering an il-6r antibody
AU2015317905A1 (en) 2014-09-16 2017-03-16 Regeneron Pharmaceuticals, Inc. Compositions for improving the health related quality of life of rheumatoid arthritis patients
IL319993A (en) 2015-11-03 2025-06-01 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
BR112018067851A2 (pt) 2016-03-07 2019-02-05 Regeneron Pharma composições e métodos para o tratamento de artrite reumatoide
EP3216461A1 (en) * 2016-03-07 2017-09-13 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis

Also Published As

Publication number Publication date
US20230059376A1 (en) 2023-02-23
CA3110891A1 (en) 2020-03-05
AU2025203365A1 (en) 2025-05-29
TWI868074B (zh) 2025-01-01
SG11202101674QA (en) 2021-03-30
TW202532441A (zh) 2025-08-16
IL280824A (en) 2021-04-29
AU2019329958B2 (en) 2025-05-29
TW202026035A (zh) 2020-07-16
PH12021550416A1 (en) 2021-09-27
MX2021002422A (es) 2021-07-15
US20200102395A1 (en) 2020-04-02
WO2020047029A1 (en) 2020-03-05
US11319375B2 (en) 2022-05-03
JP2022502350A (ja) 2022-01-11
MX2025010592A (es) 2025-10-01
EP3843852A1 (en) 2021-07-07
KR20210049871A (ko) 2021-05-06
AU2019329958A1 (en) 2021-03-18
CL2021000483A1 (es) 2021-07-19
BR112021003206A2 (pt) 2021-05-25
JP7504871B2 (ja) 2024-06-24
CN112955222A (zh) 2021-06-11

Similar Documents

Publication Publication Date Title
MA53481A (fr) Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde
EP3399923A4 (en) SYSTEM AND METHOD FOR TREATING MVO
EP3368559A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3298140A4 (en) COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CALCIFICATION DISEASES AND METHODS OF USE THEREOF
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
EP3801578A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF C. DIFFICILE
EP3867280A4 (en) METHODS OF TREATMENT OF RHEUMATOID ARTHRITIS
EP3442541A4 (en) METHOD FOR THE TREATMENT OF CANCER AND THE INHIBITION OF TRANSPLANT DISPOSAL
EP3405191A4 (en) METHOD AND COMPOSITIONS FOR TREATING HYPERHIDROSIS
EP3462883A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3681498A4 (en) PROCEDURES AND COMPOSITIONS FOR CANCER TREATMENT
EP3651795A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF CANCER WITH AN H3K27M MUTATION
EP3399993A4 (en) METHOD AND COMPOSITIONS FOR PREVENTING AND TREATING DUCHENNE MUSCLE DYSTROPHY
EP3347025A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT
EP3353204A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3688023A4 (en) PROCEDURES AND COMPOSITIONS FOR CANCER TREATMENT
EP3638293A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER
EP3373951A4 (en) METHOD AND COMPOSITIONS FOR TREATING EPIDERMOLYSIS BULLOSA
EP3801478A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF CALCIPHYLAXIA
EP3870104A4 (en) METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
EP3873205A4 (en) MATERIALS AND METHODS FOR TREATMENT OF CANCER
EP3452044A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3373922A4 (en) COMPOSITIONS AND METHODS FOR TREATING HOMOCYSTINURIA
EP3886809A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF OSTEOARTHRITIS
EP3628006A4 (en) COMPOSITIONS AND METHODS OF TREATMENT FOR RHEUMATOID ARTHRITIS